File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat

TitleThe use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat
Authors
KeywordsCombined gene therapy
Glioma
In vivo gene transfer
Nonviral vector
PEI PEGylation
Tumor targeting
Issue Date2009
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/biomaterials
Citation
Biomaterials, 2009, v. 30 n. 23-24, p. 4014-4020 How to Cite?
Abstract
Combined treatment using nonviral agent-mediated enzyme/prodrug therapy and immunotherapy had been proposed as a powerful alternative method of cancer therapy. The present study was aimed to evaluate the cytotoxicity in vitro and the therapeutic efficacy in vivo when the cytosine deaminase/5-fluorocytosine (CD/5-FC) and TNF-related apoptosis-inducing ligand (TRAIL) genes were jointly used against rat C6 glioma cells. The potency of the FA-PEG-PEI used as a nonviral vector was tested in the FR-expressed C6 glioma cells and Wistar rats. The C6 glioma cells and animal model were treated by the combined application of FA-PEG-PEI/pCD/5-FC and FA-PEG-PEI/pTRAIL. The antitumor effect was evaluated by survival assays and tumor volume. This study revealed a significant increase of cytotoxicity in vitro following the combined application of FA-PEG-PEI/pCD/5-FC and FA-PEG-PEI/pTRAIL treatments in C6 glioma cells. Animal studies showed a significant growth inhibition of the C6 glioma xenografts using the combined treatment. These results demonstrated that the combined treatment generated additive cytotoxic effect in C6 glioma cells in both in vitro and in vivo conditions, and indicated that such treatment method using both enzyme/prodrug therapy and TRAIL immunotherapy might be a promising therapeutic strategy in treating glioma. © 2009 Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/70121
ISSN
2013 Impact Factor: 8.312
ISI Accession Number ID
References

 

Author Affiliations
  1. Nanfang Hospital
  2. The University of Hong Kong
  3. Sun Yat-Sen University
  4. Chinese Academy of Medical Sciences
  5. Chinese University of Hong Kong
DC FieldValueLanguage
dc.contributor.authorLiang, Ben_HK
dc.contributor.authorHe, MLen_HK
dc.contributor.authorChan, Cyen_HK
dc.contributor.authorChen, Ycen_HK
dc.contributor.authorLi, XPen_HK
dc.contributor.authorLi, Yen_HK
dc.contributor.authorZheng, Den_HK
dc.contributor.authorLin, MCen_HK
dc.contributor.authorKung, HFen_HK
dc.contributor.authorShuai, XTen_HK
dc.contributor.authorPeng, Yen_HK
dc.date.accessioned2010-09-06T06:19:55Z-
dc.date.available2010-09-06T06:19:55Z-
dc.date.issued2009en_HK
dc.identifier.citationBiomaterials, 2009, v. 30 n. 23-24, p. 4014-4020en_HK
dc.identifier.issn0142-9612en_HK
dc.identifier.urihttp://hdl.handle.net/10722/70121-
dc.description.abstractCombined treatment using nonviral agent-mediated enzyme/prodrug therapy and immunotherapy had been proposed as a powerful alternative method of cancer therapy. The present study was aimed to evaluate the cytotoxicity in vitro and the therapeutic efficacy in vivo when the cytosine deaminase/5-fluorocytosine (CD/5-FC) and TNF-related apoptosis-inducing ligand (TRAIL) genes were jointly used against rat C6 glioma cells. The potency of the FA-PEG-PEI used as a nonviral vector was tested in the FR-expressed C6 glioma cells and Wistar rats. The C6 glioma cells and animal model were treated by the combined application of FA-PEG-PEI/pCD/5-FC and FA-PEG-PEI/pTRAIL. The antitumor effect was evaluated by survival assays and tumor volume. This study revealed a significant increase of cytotoxicity in vitro following the combined application of FA-PEG-PEI/pCD/5-FC and FA-PEG-PEI/pTRAIL treatments in C6 glioma cells. Animal studies showed a significant growth inhibition of the C6 glioma xenografts using the combined treatment. These results demonstrated that the combined treatment generated additive cytotoxic effect in C6 glioma cells in both in vitro and in vivo conditions, and indicated that such treatment method using both enzyme/prodrug therapy and TRAIL immunotherapy might be a promising therapeutic strategy in treating glioma. © 2009 Elsevier Ltd. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/biomaterialsen_HK
dc.relation.ispartofBiomaterialsen_HK
dc.rightsBiomaterials. Copyright © Elsevier BV.en_HK
dc.subjectCombined gene therapyen_HK
dc.subjectGliomaen_HK
dc.subjectIn vivo gene transferen_HK
dc.subjectNonviral vectoren_HK
dc.subjectPEI PEGylationen_HK
dc.subjectTumor targetingen_HK
dc.titleThe use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the raten_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0142-9612&volume=23-24&spage=4014&epage=4020&date=2009&atitle=The+Use+of+Folate-PEG-grafted-hybranched-PEI+Nonviral+Vector+for+the+Inhibition+of+Glioma+Growth+in+the+Raten_HK
dc.identifier.emailLin, MC:mcllin@hkucc.hku.hken_HK
dc.identifier.authorityLin, MC=rp00746en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.biomaterials.2009.04.011en_HK
dc.identifier.pmid19427690en_HK
dc.identifier.scopuseid_2-s2.0-67349190843en_HK
dc.identifier.hkuros156070en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-67349190843&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume30en_HK
dc.identifier.issue23-24en_HK
dc.identifier.spage4014en_HK
dc.identifier.epage4020en_HK
dc.identifier.isiWOS:000267469300023-
dc.publisher.placeNetherlandsen_HK
dc.identifier.scopusauthoridLiang, B=7202071217en_HK
dc.identifier.scopusauthoridHe, ML=35080389700en_HK
dc.identifier.scopusauthoridChan, Cy=22033276600en_HK
dc.identifier.scopusauthoridChen, Yc=24075600300en_HK
dc.identifier.scopusauthoridLi, XP=26663939600en_HK
dc.identifier.scopusauthoridLi, Y=36063259900en_HK
dc.identifier.scopusauthoridZheng, D=7202567084en_HK
dc.identifier.scopusauthoridLin, MC=7404816359en_HK
dc.identifier.scopusauthoridKung, HF=7402514190en_HK
dc.identifier.scopusauthoridShuai, XT=7003661316en_HK
dc.identifier.scopusauthoridPeng, Y=35249237100en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats